

Kontakt

+41797465525 (Work)
michael.mrochen@irocscience.com

www.linkedin.com/in/michael-mrochen (LinkedIn)
www.irocscience.com (Company)

Top-Kenntnisse

Start-ups
Medical Devices
Produktentwicklung

Languages

Englisch (Full Professional)
Deutsch (Native or Bilingual)

Honors-Awards

Troutman Award
Swiss Technology Award
Swiss Economic Award (Finalist)
Bronze Medal
Silver Medal 2013 & 2015

Publications

More than 140 publications can be found under ResearchGate (see link)

Patents

Multiple patents in the field of ophthalmology and vision care (see link)

Michael Mrochen

Solving Vision Problems to Improve Patients' Lives
Zug, Zug, Schweiz

Zusammenfassung

Over the past 25 years I have founded, led and worked with companies that have developed and commercialized multiple innovative ophthalmic technologies and procedures with impact. As engineer in physics, doctor of theoretical medicine and entrepreneur in ophthalmology and vision care with a large network, I am bridging the technical, clinical and commercial worlds together to achieve meaningful outcomes. In this role, I have repeatedly succeeded in developing and deploying products to the market improving the lives of countless patients worldwide.

The ophthalmic equipment market is valued at approx. USD 50 Billion. Growth in this market is due to the rapid growth in the geriatric population, rising prevalence of eye diseases, technological advancements in ophthalmic devices, increasing government initiatives to control visual impairment. About 1.5 billion people worldwide do not have access to glasses or go blind because of cataract. Around 1.8 billion people are affected by presbyopia. Progressive myopia is increasing dramatically with significant social impact on millions of children around the world. It is promising from an investor's point of view to provide financial resources for innovative products and therapies that those products can find their way to the market.

I have extensive experience working with start-ups, SMEs and large multinational companies in the field. Currently, I am a member of the board of a range of ophthalmic companies in addition to directing technology development at Allotex. I lectured at ETH Zurich for 15 years, have published over 120 articles, reports and book chapters as well as I have generated over 50 patents and patent applications. In addition, I'm also a regular key note speaker at ophthalmology events around the world.

I'm always looking for interesting contacts to expand my network and for financial resources to initiate new projects. Please do not hesitate to contact me. I look forward to hearing from you.

Berufserfahrung

Pallas Kliniken

Member of the board

Januar 2022 - Present (1 Jahr 3 Monate)

Olten, Solothurn, Schweiz

IROC Science to Innovation

20 Jahre 10 Monate

Founder & Ceo

Januar 2012 - Present (11 Jahre 3 Monate)

Co-Founder, President, General manager

Juni 2002 - Dezember 2011 (9 Jahre 7 Monate)

Zurich

www.iroc.ch

IROC - Ihre Augenlinik im Herzen von Zürich

Das Institut für Refraktive und Ophthalgo-Chirurgie (IROC) ist spezialisiert auf das breite Spektrum der Augenheilkunde. Wir haben für jeden Themenbereich den Spezialisten vor Ort: Katarakt, Glaukom, Hornhauterkrankungen, Augenlid, Augenlaser oder Makulatherapie, wir bieten alles an. Egal ob Sie einen rundum Check-up wollen oder einen Spezialisten für Ihr Anliegen suchen, bei uns finden Sie Ihren passenden Augenarzt.

aescuvest

Member of Investment Committee

März 2021 - Present (2 Jahre 1 Monat)

<https://www.aescuvest.eu>

Vivior AG

Chairman Of The Board

April 2017 - Present (6 Jahre)

Zürich und Umgebung, Schweiz

<http://vivior.com/>

Renowned and independent keynote speaker at trade events, congresses and conferences

Keynote Speaker

1996 - Present (27 Jahre)

Around the world

- o Wavefront Conference
- o Corneal crosslinking conference
- o American Academy of Ophthalmology
- o European Society of Cataract and Refractive Surgery
- o American Society of Cataract and Refractive Surgery
- o Asian Pacific Academy of Ophthalmology
- o Ophthalmology Future Forum
- o American- European Congress of Ophthalmic Surgeons

ANREPA ASSET Management AG

Member of the Board of Directors

Juni 2016 - Present (6 Jahre 10 Monate)

Hergiswil NW, Kanton Nidwalden, Schweiz

ANREPA is an investment boutique focused on the stock market offering a disciplined investment process for long term oriented investors.

Allotex

Co-Founder

Juni 2016 - Present (6 Jahre 10 Monate)

Boston, Massachusetts, Vereinigte Staaten von Amerika

Our tissue addition technology uses precisely-shaped human corneal allografts to create an essentially permanent, living contact lens.

ETH Zurich

Lecturer

März 2002 - 2017 (15 Jahre)

Zürich

Medical optics, laser in medicine

ClearSight Innovations Ltd

CTO, co-Founder

April 2013 - Oktober 2015 (2 Jahre 7 Monate)

Dublin

www.clearsightinnovations.com

The original inspiration for the ClearSight technology came from two Irish based ophthalmic surgeons. A collaborative research agreement to develop the concepts with NDRC (National Digital Research Centre), the Applied Optics Group at NUI Galway and the surgeons ensued.

ClearSight Innovations Ltd. was formed as a standalone company in 2013 to progress the technology. It is headquartered in Dublin with offices in both Dublin and Zurich.

ClearSight Innovations is developing new technologies that allow accurate measurement of the eye with the ability to move cataract surgery outcomes to a new level. Cataract surgery is the most commonly performed surgery in the world with over 20 million surgeries conducted annually.

The founders of ClearSight Innovation achieved a successful exit in 2015 to a larger company.

IROC Innocross AG

President, Owner

2011 - Oktober 2015 (4 Jahre)

IROC Innocross was the first company to commercialize a cross-linking device for the treatment of keratoconus and other corneal pathologies. To date, IROC Innocross has sold its UV-X devices to more than 1,000 ophthalmologists giving it the largest installed base of cross linking devices in the world.

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it has purchased the assets of IROC Innocross AG, of Zug, Switzerland.

WaveLight, Inc.

Consultant

1996 - Oktober 2015 (19 Jahre)

Technical aspects of the WaveLight FS200 femtosecond laser.

Mrochen M, Wüllner C, Krause J, Klafke M, Donitzky C, Seiler T.

J Refract Surg. 2010 Oct;26(10):S833-40. doi:

10.3928/1081597X-20100921-12

Aberration-sensing and wavefront-guided laser in situ keratomileusis:

management of decentered ablation. Mrochen M, Krueger RR, Bueeler M, Seiler T.

J Refract Surg. 2002 Jul-Aug;18(4):418-29.

Clinical results of wavefront-guided laser in situ keratomileusis 3 months after surgery.

Mrochen M, Kaemmerer M, Seiler T.

J Cataract Refract Surg. 2001 Feb;27(2):201-7.

Focuszone

Founder

2009 - 2011 (2 Jahre)

<http://www.focuslaser.ch/de/>

University of Zurich

Postdoc

März 2000 - Februar 2002 (2 Jahre)

Zürich

Biomechanics, cross linking, laser refractive surgery, contact lenses

TU Dresden

5 Jahre 1 Monat

Postdoc

März 1999 - Februar 2000 (1 Jahr)

Dresden

Wavefront, laser tissue interaction, scanning systems, refractive surgery

Phd Candidate

Februar 1995 - März 1999 (4 Jahre 2 Monate)

Dresden

Mid infrared solid state lasers for ophthalmic applications

University of Jena

Research Fellow

Dezember 1994 - Dezember 1995 (1 Jahr 1 Monat)

Jena

Institute of Optics and Quantum Electronics

Femtosecond spectroscopy

Aesculap Meditec

Praktikant

1992 - 1994 (2 Jahre)

Heroldsberg, Germany

Mid infrared solid state lasers

Ausbildung

ETH Zürich

Habilitation · (2000 - 2004)

Technische Universität Dresden

Promotion, Medizinische Physik · (1996 - 1999)

FH Isny

Dipl. Ing., Physics · (1990 - 1994)